Objectives: the study aims to estimate the clinical-impact and cost-effectiveness value of
adding human papillomavirus 16/18 vaccination against cervical cancer among women …

INTRODUCTION: Two vaccines for primary prevention of cervical cancer are available in
France, Gardasil® and Cervarix®, since 2007 and 2008 respectively. Currently, the French …

Background: oncogenic, ie high risk human papillomavirus (hrHPV) types are the major
cause of invasive cervical cancer (ICC). Putatively licensable vaccines against the hrHPVs …

Background To eliminate cervical cancer as a public health problem, the World Health
Organization had recommended routine vaccination of adolescent girls with two doses of the …

Objective. To evaluate the likely cost-effectiveness of introducing routine HPV vaccination in
Iceland. Design. Prospective cost-effectiveness analysis of human papilloma virus (HPV) …

Background: Despite screening, cervical cancer (CC) remains a serious health care
problem. Because human papillomavirus (HPV) is the necessary cause of CC, the …

Objectives China suffers from high burdens of human papillomavirus (HPV) and cervical
cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV …

We evaluated the cost-effectiveness of combining a cervical cancer screening programme
with a national HPV vaccination programme compared to a screening programme alone to …

Background Current prophylactic vaccines against human papillomavirus (HPV) target two
of the most oncogenic types, HPV-16 and-18, which contribute to roughly 70% of cervical …

Public health measures to prevent cervical cancer (CC) currently rely on early detection and
excision of precancerous lesions. The recent identification of oncogenic HPV infections as a …